Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,365 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Not listed No phase listed Observational Accepts healthy volunteers

S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues

NCT04666532
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Alternate Day Micafungin: A PK Study in Pediatric Patients

NCT00842504
View directory record Official record
Conditions
Fungal Infection
Interventions
Micafungin
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
29 Days to 10 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms

NCT04430855
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 25, 2026, 1:52 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Azithromycin in Control of Trachoma II

NCT00286026
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 25, 2026, 1:52 AM EDT
Recruiting Phase 1 Interventional

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

NCT07049575
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ruxolitinib Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Fountain Valley, California • Northridge, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 25, 2026, 1:52 AM EDT
Terminated Phase 4 Interventional Results available

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

NCT03756454
View directory record Official record
Conditions
Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions
Bezlotoxumab, Normal Saline
Biological · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacterial Genomic Sequencing in Overactive Bladder

NCT01642277
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solifenacin
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 25, 2026, 1:52 AM EDT
Withdrawn No phase listed Observational

Study to Evaluate Bacterial Activity That Drives the Progression of Clinical Infection

NCT03854695
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 25, 2026, 1:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of NAATs for Detection of C. Trachomatis and N. Gonorrhoeae From Pharynx, Rectum, Glans & Urethra of MSM

NCT00187902
View directory record Official record
Conditions
Sexually Transmitted Diseases, Chlamydia, Gonorrhea
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)

NCT03950856
View directory record Official record
Conditions
Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
V114, Prevnar 13™
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
2,340 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
30
States / cities
Chandler, Arizona • Mesa, Arizona • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 25, 2026, 1:52 AM EDT
Completed No phase listed Observational Results available

A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.

NCT05873751
View directory record Official record
Conditions
Gonorrhea, Chlamydia, Meningococcal Vaccines
Interventions
Trumenba Vaccine, MenACWY Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
15 Years to 30 Years
Enrollment
1,307,378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 25, 2026, 1:52 AM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Sonelokimab
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
12 Years and older
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
49
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 25, 2026, 1:52 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pathobiomes in Gut of Critically Ill Patients

NCT06822465
View directory record Official record
Conditions
Pseudomonas Aeruginosa
Interventions
P. aeruginosa using in vitro and in vivo assays
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Hyde Park, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Female Urogenital Nutrition- Health Study

NCT05015400
View directory record Official record
Conditions
Bacterial Urinary Tract Infection
Interventions
Plain Water
Other
Lead sponsor
Arizona State University
Other
Eligibility
18 Years to 34 Years · Female only
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Not applicable Interventional

HeRO Vascular Access Device Bacteremia Study

NCT00889564
View directory record Official record
Conditions
Hemodialysis
Interventions
HeRO Vascular Access Device
Device
Lead sponsor
Merit Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Miami, Florida • Atlanta, Georgia • Springfield, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis

NCT02432807
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vancomycin 1.1%, Placebo
Drug
Lead sponsor
Kurobe LLC
Industry
Eligibility
1 Year and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
16
States / cities
Paramount, California • Petaluma, California • Rancho Cordova, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Weight-Based, Dose-Escalation Study With Intravenous ETI-204 in Adult Volunteers

NCT01453907
View directory record Official record
Conditions
Anthrax
Interventions
ETI-204, "Anthim", placebo
Drug
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 25, 2026, 1:52 AM EDT
Completed No phase listed Observational

Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia

NCT01140022
View directory record Official record
Conditions
Chlamydia, Screening
Interventions
CT Screening
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 25 Years · Female only
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Fresno, California • Oakland, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Taking of blood samples, Boostrix, Adacel
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
28 Years to 73 Years
Enrollment
1,954 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
37
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Partnership for Rapid Elimination of Trachoma

NCT00792922
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 5 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 25, 2026, 1:52 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Novel Female Hygiene Device for Postcoital Discomfort

NCT04885556
View directory record Official record
Conditions
Vaginal Discharge, Dyspareunia, Female Sexual Dysfunction, Vaginitis, Bacterial Vaginoses
Interventions
Tampon-like device for absorption of sexual fluids
Device
Lead sponsor
Atlantic Health System
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 25, 2026, 1:52 AM EDT